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Abstract
Objectives We report the 3-year clinical experience of a
large new Danish PET/CT centre without capacity limi-
tations in relation to national and European developments.
Methods The use of PET/CT in cancer was registered from
early 2006 to early 2009 to judge the impact on patient
management and to compare it with national and European
trends.
Results 6056 PET/CT examinations were performed in
4327 patients. Activity increased by 86 examinations per
month compared with the same month the year before.
Referrals came primarily from oncology (23.0%), haema-
tology (21.6%), surgery (12.6%), internal medicine (12.7%)
and gynaecology (5.5%). Referral indications were diagno-
sis (31.3%), staging (22.3%), recurrence detection (21.2%),
response evaluation (17.0%) and other (8.2%). Response
from nearly 60% of users showed that PET/CT caused a
change in diagnosis and/or staging and/or treatment plan in
36.0% of cases. During the study period, there was a steep
increase in the national use of FDG and in the European use
of PET/CT.
Conclusions We recorded a constantly increasing use of
PET/CT that caused a change in diagnosis and/or staging
and/or treatment plan in 36.0% of cases. In line with
national and European trends this may suggest a shift in
favour of functional rather than anatomical imaging.
Keywords Radionuclide imaging . PET/CT. Referral
pattern . Indications . Clinical impact
Introduction
The combination positron emission tomography/computed
tomography (PET/CT) has changed nuclear medicine and
focused on the diversities of functional and anatomical
imaging and the advantages of combined imaging with
image fusion. By 2005, stand-alone PET systems were no
longer produced. In 2005, the US Centers of Medicare and
Medicaid Services decided to give coverage to FDG PET in
several cancers with the clause that its use be registered in a
“National Oncologic PET Registry” [1, 2]. With the
growing use of PET/CT worldwide and the advent of new
tracers for more specific imaging procedures guidance has
been given on both sides of the Atlantic [3–5] and a debate
on how to monitor cancer therapy by functional rather than
anatomical imaging is developing [6–8].
In the Nordic countries, the first PET facilities were
established in Stockholm and Uppsala (in the late 1970s–
early 1980s) followed by Turku (1988), Copenhagen
(1989) and Aarhus (1993), mainly focusing on brain
research except for a broader profile in Turku which
became a national research institution in 1996 [9–11]. In
Denmark, clinical application lagged behind until 4 years
ago, when politicians suddenly realised that cancer man-
agement in this country was slow, insufficient and for some
cancers blemished by unacceptably poor survival rates.
Consequently, the Danish government announced that
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cancer should be treated as an acute disease. To prevent
bottlenecks in the public healthcare system providing more
than 98% of hospital services, the five Danish regions
decided in 2007 on a “National Danish Invitation to Tender
for the Deliver of Cancer Scanners” which doubled the
Danish stock of PET/CT systems. Alongside this, the
Danish National Board of Health decided to establish
National Integrated Pathways for cancer management, 34
of which were finished in 2009. Against this background,
we report our experiences from the first 3 years of
existence of a new and large PET centre in Odense,
Denmark, and compare these activities with available
data from the Danish Institute of Radiation Protection
[12] and from the European Association of Nuclear
Medicine (EANM) [13–15].
Materials and methods
Denmark has approximately 5.5 million inhabitants spread
over a peninsula (Jutland with Aarhus as the main town),
two major islands (Funen with Odense and Zealand with
the capital Copenhagen) and several smaller islands. It
comprises five administrative regions: Capital, Zealand,
Southern, Central and North. Our Department of Nuclear
Medicine is situated in Odense in the middle of Funen with
its 500,000 inhabitants. Odense University Hospital (OUH)
is the largest hospital on Funen and in the Region of
Southern Denmark (1.2 million inhabitants) and represents
together with Svendborg Hospital in Southern Funen the
largest administrative hospital unit in Denmark.
OUH is part of the University of Southern Denmark, the
third largest university in Denmark, and is home to one of
five major cancer centres in Denmark. Against this
background it was decided to build a new PET centre with
cyclotron and radiochemical facilities, and on 28 February
2006 the first patient was examined by PET/CT. During the
first year, all examinations were performed with a single
PET/CT (General Electronic Discovery STE PET/CTwith a
Continuum VCT 16 slice CT) using exclusively 2-deoxy-2-
[18F]-fluoro D-glucose (FDG) produced at the cyclotrons at
Rigshospitalet in Copenhagen or at Risø DTU National
Laboratory in Roskilde, until permission for local produc-
tion in Odense was granted by the Danish Medicines
Agency. In early 2007, two additional PET/CT systems
were added (General Electric Discovery VCT 64 slice CT
and Discovery Rx 64 slice CT). From the second year on,
FDG was produced in Odense and a few other tracers
([18F]DOPA, [18F]choline, and [18F]fluoride) were grad-
ually introduced into clinical practice. All patients fasted
6 h before examination and rested approximately 1 h after
the intravenous injection of tracer. All underwent whole-
body or partial-body imaging from the base of the skull to
mid-thigh. All patients who could tolerate a contrast agent
received this intravenously and orally, and all patients with
known or suspected malignancies allowing measurement of
tumour size had a diagnostic CT at least on their first visit.
Dual time PET, i.e., early and late acquisition was not
applied. The reports were generated jointly by a nuclear
medicine physician and a radiological specialist.
Data from all examinations were collected consecutively
and prospectively on pre-defined case report forms com-
prising questions regarding working diagnosis, purpose of
the PET/CT investigation (diagnosis, staging, recurrence
detection, response assessment, etc.), and the imaging
process (before, during and after). Feedback from the
referring clinical departments or practitioners was collected
to evaluate if the PET/CT did confirm and/or lead to
changes in the working diagnosis, staging and/or the
treatment plan. This was done by sending the referring
departments a special form together with the PET/CT
report. If the form was not returned, departments were
requested to answer twice within a half year. If this was
unsuccessful, the answer was considered lost. Statistical
analyses were basically of descriptive nature. Exploratory
Cochran-Armitage trend tests were performed at a signif-
icance level of 5% (two-sided testing) without adjustment
for multiplicity. All analyses were done in SAS©, version
9.1.3.
Available data for comparison were collected from the
Danish Institute of Radiation Protection in the shape of the
recorded yearly use of FDG and other PET radiopharma-
ceuticals [12], as well as from the EANM, which from the
years 2006, 2007 and 2009 (no data from 2008) retrieved
data on the use of PET and PET/CT from an increasing
number of European member societies, including the
number of various types of systems and imaging made by
each technique [13–15].
Results
Imaging
A total of 6056 PET/CT were performed in 4327 patients,
3459 (79.9%) of whom had only one scan, whereas 868
(20.1%) had two or more examinations, for details see
Table 1 which displays the number of examinations in
relation to the working diagnosis according to level 2 of the
International Classification of Diseases, version 10 (ICD-
10) [16]. In almost half of patients with three or more PET/
CT, the working diagnosis was “Neoplasms of lymphoid,
haematopoietic and related tissue”, whereas the working
diagnoses of the remaining patients were distributed in
small portions. The number of investigations peaked in
January, February and October, each with approximately
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10%–11% of the yearly production, whereas March (6%),
April (6.6%) and July (6.5%) were the least busy months.
Patient disposition
There were 2113 (48.8%) female and 2214 (51.2%) male
patients, and 35 patients (0.8%), 7 girls and 28 boys, below
an age of 18 years (range 1–17). The mean age (5th and
95th percentiles) of female and male patients was 62.6 years
(36 to 83 years) and 63.5 years (35 to 82 years),
respectively. Body mass index (kg · m−2) was 24.7 (18.0
to 34.6) in female and 25.5 (19.3 to 32.9) in male patients.
All examined patients were referred with known or
suspected cancer. The frequencies of reported co-
morbidities were as follows: allergy 17.5%, diabetes
9.1%, cardiac disease 15.4%, arterial hypertension 29.7%,
hypercholesterolaemia 17.1% and reduced kidney function
6.3% (multiple indications in single patients possible).
Moreover, 30.9% of patients had undergone an operation
within the last 2 months before imaging, 1.0% had
undergone radiation therapy and 1.2% chemotherapy.
Referrals
Most referrals (4965 out of 6056, or 82.0%) were received
from OUH, 492 (8.1%) from other Funen hospitals, 510
(8.4%) from other hospitals in the Region of Southern
Demark and 21 (0.3%) from hospitals in other regions of
Demark. Additionally, 47 (0.8%) came from General
Practitioners, and 7 (0.1%) from practicing specialists in
the region. About 75% of referrals came from oncology
(23.0%), haematology (21.6%), surgery (12.6%), internal
medicine (12.7%) and gynaecology (5.5%).
Indications
Classifying according to level 1 of the ICD-10, 5571
(92.0%) and 291 (4.8%) patients had working diagnoses
belonging to the classes “Neoplasms” (C00-D48) and
“Symptoms, signs and abnormal clinical and laboratory
findings, not elsewhere classified” (R00-R99), respectively.
Refining the classification of diseases to a lower level
indicated that 10.8% had known or suspected malignan-
cies in the digestive organs (C15-C26), 18.9% in the
respiratory and intrathoracic organs (C30-C39), 10.2% in
the female genital organs (C51-C58), whereas 8.1% were
classified as having neoplasms of ill-defined, secondary
and unspecified sites (C76-C80), and 23.1% cancer of
lymphoid, haematopoietic and related tissue (C81-C96)
(see Table 2). Most patients were referred for PET/CT
with a known disease (N=4397 (72.6%)), whereas
approximately every fourth patient was referred with an
expectation about disease (N=1602 (26.4%)). MostTa
b
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patients with known disease belonged to the classes
digestive organs (10.0%), respiratory and intrathoracic
organs (8.1%) and neoplasms of lymphoid, haematopoietic
and related tissue (21.3%), whereas codes of cancer in
respiratory and intrathoracic organs (10.7%), female
genital organs (2.3%), and neoplasms of ill-defined,
secondary and unspecified sites (5.0%) were most pro-
nounced in patients with expected disease.
The purpose of referring the patient for PET/CT was
diagnosis alone in 31.3% of patients, staging alone in
22.3%, recurrence detection alone in 21.2%, or response
assessment alone in 17.0%, whereas combinations of these
or target definition, follow-up, or research appeared to be
the reason for the remaining 8.2%. Diagnosis was the main
purpose in lung cancer, cancer of unknown primary, and
patients presenting with “General symptoms and signs” (see
Table 3). Staging was the main purpose in patients with
malignant lymphomas and lung cancer, whereas detection
of recurrence was the main purpose in patients with cancer
in digestive organs and neoplasms of lymphoid, haemato-
poietic and related tissue. Response evaluation was the
main reason for imaging in patients with neoplasms of
lymphoid, haematopoietic and related tissue.
Tracers, systems, procedures
FDG was by far the most commonly used tracer (N=
5933 (98.0%)), whereas other tracers were produced and
used on occasion ([18F]choline: N=82 (1.4%), [18F]
DOPA: N=25 (0.4%), [18F]fluoride: N=11 (0.2%)).
System no. 1 was used most (N=3349 (55.3%)) followed
by systems no. 2 (N=1653 (27.3%)) and no. 3 (N=1028
(17.0%)). Diagnostic CT was more frequently used (N=
3613 (59.7%)) than low-dose CT. Oral contrast medium
was also used in most cases (N=3521 (58.1%)). Intrave-
nous contrast medium was used in more than every second
Table 2 Working diagnosis of referred patients according to the International Classification of Diseases, version 10 (ICD-10) [16]
ICD Code Title All referrals Known disease Expected disease Missing
All 6056 (100%) 4397 (72.6%) 1602 (26.5%) 57 (0.9%)
C00-C14 Lip, oral cavity and pharynx 90 (1.5%) 78 (1.3%) 11 (0.2%) 1 (0.02%)
C15-C26 Digestive Organs 654 (10.8%) 604 (10.0%) 46 (0.8%) 4 (0.07%)
C30-C39 Respiratory and intrathoracic organs 1147 (18.9%) 493 (8.1%) 649 (10.7%) 5 (0.08%)
C43-C44 Skin 293 (4.8%) 284 (4.7%) 8 (0.1%) 1 (0.02%)
C50-C50 Breast 229 (3.8%) 212 (3.5%) 14 (0.2%) 3 (0.05%)
C51-C58 Female genital organs 622 (10.3%) 479 (7.9%) 139 (2.3%) 4 (0.07%)
C60-C63 Male genital organs 195 (3.2%) 191 (3.2%) 2 (0.03%) 2 (0.03%)
C64-C68 Urinary tract 274 (4.5%) 244 (4.0%) 25 (0.4%) 5 (0.08%)
C73-C75 Thyroid and other endocrine glands 77 (1.3%) 61 (1.0%) 15 (0.2%) 1 (0.02%)
C76-C80 Malignant neoplasms of ill-defined, secondary and unspecified sites 498 (8.2%) 190 (3.1%) 303 (5.0%) 5 (0.08%)
C81-C96 Malignant neoplasms, stated or presumed to be primary, of lymphoid,
haematopoietic and related tissue
1407 (23.2%) 1288 (21.3%) 108 (1.8%) 11 (0.2%)
R50-R69 General symptoms and signs 288 (4.8%) 148 (2.4%) 135 (2.2%) 5 (0.08%)
Z00-Z13 Persons encountering health services for examination and investigation 79 (1.3%) 6 (0.1%) 73 (1.2%) 0 (0%)
Table 3 Reasons for referral to PET/CT in relation to working diagnosis
ICD Code Title All referrals Diagnosis Staging Recurrence Response Combinations
or other
All 6056 (100%) 1898 (31.3%) 1349 (22.3%) 1281 (21.2%) 1028 (17.0%) 500 (8.2%)
C15-C26 Digestive Organs 654 (10.8%) 48 (0.8%) 165 (2.7%) 271 (4.5%) 89 (1.5%) 81 (1.3%)
C30-C39 Respiratory and intrathoracic organs 1147 (18.9%) 630 (10.4%) 269 (4.4%) 173 (2.9%) 32 (0.5%) 43 (0.7%)
C51-C58 Female genital organs 622 (10.3%) 132 (2.2%) 179 (3.0%) 181 (3.0%) 87 (1.4%) 43 (0.7%)
C64-C68 Urinary tract 274 (4.5%) 24 (0.4%) 182 (3.0%) 47 (0.8%) 10 (0.2%) 11 (0.2%)
C76-C80 Malignant neoplasms of ill-defined,
secondary and unspecified sites
498 (8.2%) 438 (7.2%) 9 (0.1%) 16 (0.3%) 19 (0.3%) 16 (0.3%)
C81-C96 Malignant neoplasms, stated or
presumed to be primary, of
lymphoid, haematopoietic
and related tissue
1407 (23.2%) 108 (1.8%) 277 (4.6%) 231 (3.8%) 659 (10.9%) 132 (2.2%)
R50-R69 General symptoms and signs 288 (4.8%) 274 (4.5%) 0 (0%) 2 (0.03%) 1 (0.02%) 11 (0.2%)
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patient (N=3246 (53.6%)). Actually, in 3172 patients
(52.4%) diagnostic CT, oral contrast medium and intrave-
nous contrast medium were used together, whereas
diagnostic CT and oral contrast medium were only used
in 326 patients (5.4%) without intravenous contrast
medium. In 3418 examinations (56.4%), imaging fields 2
to 5 were used, whereas 1 to 5 were used 2323 times
(38.4%) and 1 to 7 were used 86 times (1.4%).
The examination was performed without any discomfort
4961 times (81.9%), whereas minor problems (discomfort,
anxiety, phobia, issues with needle insertion or injection of
x-ray contrast medium, technical problems with the
hardware and/or software) were reported 512 times
(8.5%), while data were missing in the remaining 9.6%.
Side effects like nausea following administration of
intravenous or oral contrast medium (with and without
vomiting) or an allergic reaction at the puncture wound
following administration of intravenous contrast medium
were observed in only 20 examinations (0.3%). The quality
of the imaging was “fine” in 4719 cases (77.9%),
“acceptable” in 189 cases (3.1%), and led to a repeat
acquisition in only 8 cases (0.1%), while data were
missing in the remaining cases. The PET/CT report was
considered “clear” by the referring physicians/depart-
ments in 3291 examinations (54.3%) and unclear in 191
examinations (3.2%), whereas 2574 (42.5%) readings
were not judged.
Clinical impact
Feedback on 3559 cases (58.8%) was obtained from the
referring departments. According to these responses, the
PET/CT examination confirmed the working diagnosis in
1911 cases (53.7%), the staging in 1518 (42.7%) and the
treatment plan in 1774 cases (49.9%), respectively, and
caused a change in diagnosis in 508 (14.3%), staging in 788
(22.1%) and treatment plan in 1007 cases (28.3%) (Fig. 1).
The result of PET/CT changed at least one of them
(diagnosis and/or staging and/or treatment plan) in 36.0%
of cases. Diagnostic CT was used in 51.3% of these
applying intravenous and oral contrast in 86.1%.
Trends
With an increasing number of systems the number of
examinations grew over time, i.e., from 971 in year 1 to
2020 and 3065 in year 2 and 3, respectively. The working
diagnoses varied little except for a decrease in cancer in
digestive organs from 15.8% in year 1 to 8.6% in year 3 (p<
0.0001), in skin cancers from 6.4% in year 1 to 3.9% (p=
0.0003) and in neoplasms of ill-defined, secondary and
unspecified sites from 10.4% to 7.8% (p=0.03), whereas
there was an increase in “General symptoms and signs” from
0.7% in year 1 to 6.7% in year 3 (p<0.0001). Regarding
referrals, for only 3 referring departments at OUH did the
rate of referrals differ over time: The outpatient clinics of
Gynaecologic Oncology (from 0% in year 1 to 5.2% in year
3, p<0.0001), Oncology (from 24.4% in year 1 to 20.5% in
year 3, p=0.04), and Urology (from 0% in year 1 to 3.7% in
year 3, p<0.0001)
There was a tendency for an increase in confirmation
rate of PET/CT over time and, conversely, a tendency for
decrease in the rate of change caused by PET/CT in
diagnosis, staging and treatment (Table 4). The use of other
tracers than FDG did not increase during this period.
Diagnostic CT was more frequently used than low-dose CT
during all 3 years and the use of oral contrast increased
from 49.4% in year 1 to 59.2% in year 3.
Danish use of PET radiopharmaceuticals
The use of FDG and other PET radiopharmaceuticals
reflected a relatively low and fairly constant level of
activity until 2004–2005 followed by a steep increase of
approximately 55% each year in 2006, 2007 and 2008,
albeit with a limited use of tracers other than FDG (see
Fig. 3) [15].
European tendencies
According to EANM, there was from 2006 to 2009 a
decrease in the stock of PET systems, from 163 (in 26
countries) to 145 (in 35 countries) and an increase in PET/
CT systems from 166 (in 27 countries) to 463 (in 35
countries) (+179%). Similarly, there was from 2007 to 2009
an increase in the number of PET+PET/CT from 352,872 to
597,874 (+69% despite lacking data from Belgium and the
Netherlands) [12–14].
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Fig. 1 Reported use of FDG PET/CT for diagnosis, staging, detection
of recurrence and response evaluation. The y-axis displays the
percentage of examinations
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Discussion
With fluctuations, the use of PET/CT in Odense increased
linearly since the beginning with one system in early 2006.
With the addition of two systems in 2007 capacity
limitations did not appear within the first 3 years. Instead,
the number of examinations increased on average by 86
each month compared with the same month the year before
(Fig. 2). Not surprisingly, oncology and haematology were
the most common reasons for use of PET/CT followed by
surgery (mainly breast and colorectal cancer), internal
medicine (mainly lung cancer) and gynaecology (ovarian,
cervical and uterine cancer). These specialties accounted for
about 3/4 of all referrals. Most PET/CT were made in
patients with known disease, i.e. primarily haematological
cancers and cancers in the digestive organs, the respiratory
organs, the female genitals and the breasts, accounting for
21.3%, 10.0%, 8.1%, 7.9% and 3.5%, respectively. Among
patients with unknown disease, most had suspected cancer
in the respiratory tract (10.7%), ill-defined neoplasms
(5.0%) and cancer in the female genitals (2.3%), followed
by patients with general symptoms and signs (2.2%)
(Table 2). PET/CT for diagnosis was mainly applied early
in lung cancer, while staging and recurrence detection was
more evenly used among the most common cancers,
whereas response evaluation was the purpose almost
exclusively in malignant lymphomas with sporadic use
also in gastro-intestinal and female genital cancer (Table 3).
With regard to clinical impact our survey was somewhat
blemished by a relatively high percentage of missing
answers (41.3%). Moreover, the distinction between indi-
cations (diagnosis, diagnosis/staging, or staging alone) was
not always clear cut, as consensus on definitions of terms
could for practical reasons not be made beforehand, and
also because the timing of PET/CT in the work-up varied
from one type of cancer to another. Over the 3 years, we
observed a slight increase in the proportion of patients who
had confirmation of what was expected by the clinicians,
whereas the proportion of benefit for PET/CT with regard
to change in diagnosis, staging and treatment plan
decreased from year 1 to a slightly lower, but similar, level
in year 2 and 3 (Table 4). Overall, FDG PET/CT was found
to change the working diagnosis, staging and treatment plan
in 14.3%, 22.1% and 28.3% of cases, respectively, causing
a change in at least one of them in 36.0% of the cases,
which the referring departments were able to judge. They
indicated that they could not do this in 10%–16% of cases
and in another 3%–4% they did not provide an answer.
Table 4 Trends for rate of confirmation and rate of change in diagnosis, staging and treatment plan over the 3 years
Year 1 Year 2 Year 3 Test for trend
Confirmation Diagnosis 51.0% 54.5% 54.7% P=0.13
Staging 37.6% 45.6% 42.5% P=0.06
Treatment plan 45.3% 51.8% 50.6% P=0.03
Change Diagnosis 16.3% 13.4% 13.9% P=0.16
Staging 27.4% 20.7% 20.1% P<0.001
Treatment plan 32.6% 27.6% 25.9% P=0.0012
Change in at least one of them Diagnosis and/or staging and/or treatment plan 41.0% 34.3% 34.4% P<0.0001
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These kinds of figures were not given in previous single-
centre studies on early experience with PET without CT
reporting 90% and 71% response rates in 517 and 743 cases
[17, 18], respectively, or in a twin-centre study with a return
rate of just 22% in 1500 cases [19]. Representing the
experience of a community centre [17] and tertiary centres
[18, 19] previous authors reported a change in manage-
ment/therapy in 45% [17] and 43% [18], respectively, and a
change in management in 39% and in therapy in 10% of
cases [19]. In an American single-centre study of 248 out of
an unknown number of cases, intended management was
changed in 61% of patients [20]. The question of false
positive rates with PET/CT and its ability to distinguish
malignant from non-malignant abnormalities was not
addressed in the previous studies or in our survey. The
reason was for our part that follow-up with histopatholog-
ical diagnosis and/or long term clinical outcome in all
patients was beyond our practical possibilities.
Our study is the first to report the impact of PET/CT in a
large consecutive series of patients. A similarly large survey
from Australia observed that indications for PET/CT
largely reflected Medicare reimbursement policy; however,
this study did not record changes in patient handling after
imaging [21]. As a whole, the cited studies vary to a degree,
making proper comparison virtually impossible except that
all studies reported substantial changes in management and/
or therapy albeit without definition and partition of these
terms. Our finding of a change in diagnosis/staging or
treatment plan in 36.0% of cases corresponds with the
initial results of the National Oncologic PET Registry in the
USA based on data from 22,975 studies (83.7% PET/CT)
according to which physicians changed their intended
management in 36.5% of cases after PET [22]. Focusing
on therapy alone, our referring physicians reported a change
in treatment plan in 28.3% cases compared with a switch in
physician-intended treatment after about 26.5% of imaging
procedures in the PET Registry cases [23]. Although highly
relevant, the degree PET/CT could displace other imaging
was not covered in our or any of the previous surveys. An
indication appears in a large health technology assessment
from the UK, which concluded that PET/CT did in general
improve accuracy by 10–15% over PET in six cancers and
that PET/CT has higher sensitivity and accuracy than CT/
MRI in a variety of cancers [24]. Accordingly, in the PET
Registry article on the impact on management, after 90% of
imaging procedures, referring physicians indicated that the
imaging results allowed them to avoid other imaging or
invasive procedures [23].
The very pronounced increase in number of PET/CT
examinations that we observed during all 3 years was
accompanied by only minor changes in how PET/CT was
used. We did not manage to introduce to a noticeable
degree any of the many promising new tracers that are
constantly reported in the literature. Surprisingly, this
tendency was a national one for the same years (Fig. 3).
Thus, apparently the two oldest medical cyclotron and
radiochemical facilities in Denmark (in Aarhus and Copen-
hagen) did not change their production profile during these
3 years while two more recent ones, established 2006-7 in
Odense and at Risø National Research Centre in Roskilde,
were too new to manage the introduction of new radio-
pharmaceuticals during the period in question. In Odense,
the use of non-FDG tracers increased only from 2 (0.03%)
in 2006 to 82 (2.7%) in 2008. Nationwide, this may reflect
that the introduction of new PET tracers is a time-
consuming and costly affair, not to mention difficulty in
obtaining permission from the Medicines Agencies which
consider radiopharmaceuticals on a par with drugs in
general, a notion that may seriously threaten the future of
molecular imaging [25]. From being behind at the start of
the millennium, a growing political focus on cancer
doubled the country’s stock of PET/CT systems within
3 years. However, even with this high density of equipment
the yearly need in 2008-10 of 38,000 PET estimated by the
FDG PET      Other tracers 
Fig. 3 The development of PET
and PET/CT examinations in
Denmark with FDG and tracers
other than FDG [16]. Since
2005 the average annual
increase in FDG PET and FDG
PET/CT has been 55%
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Danish Board of Health in 2006 cannot be met unless the
equipment is utilised more efficiently than the assumed
maximal production of 1,200 PET/CT per system and
year [26]. The real need is hard to judge, as it depends on
the usefulness of pipeline tracers and clinical trials in
progress. Obviously, more evidence-based knowledge is
called for to convince potential users of the benefits of
PET/CT.
The trend in Europe as a whole has been strikingly rapid
despite many countries in which the number of systems and
use of PET/CT are still far behind the average for Europe
[13–15]. Commercial market analyses foresee a promising
future for the European nuclear imaging equipment market,
which was valued at $498.9 m in 2008. It was forecast to
grow by 16% annually for the next 7 years to reach $1.4
billion by 2015, a growth that will “primarily be driven by
increasing utilisation of SPECT/CT and PET/CT, the
increase in the number of cancer patients across Europe,
technological advances, and improvements in the quality of
care” [27]. A forecast sponsored by the European Associ-
ation of Nuclear Medicine on “The medical use of radio-
pharmaceuticals up to 2025” points in the same direction
[28]. Experts anticipate that multiple techniques like PET/
CT and even PET/MRI will play a central part in diagnostic
imaging in the near future and that the use of PET/CT will
increase significantly and that of SPECT/CT slightly,
whereas other large scale techniques like CT, MRI, SPECT
alone and ultrasound will decrease over the entire period
from 2008 to 2025. Industrial respondents and interviewees
that use these techniques indicate that this is currently the
strongest development and that developments in multiple
techniques seem to promote the progress of PET [28].
Although suggestive, these predictions might be taken with
a grain of salt when we remember the impressive progress
made with CT in recent years, although many wrote off this
modality in the 1990s.
In our first 3 years, FDG was the dominating tracer and
cancer by far the disease most commonly examined.
However, according to a recent survey on multiple
technique imaging in Europe, clinical PET or PET/CT was
used also for neurology, infection/inflammation and cardi-
ology purposes by 39%, 30% and 25% of responding
members of the European Society of Radiology and by
60%, 54% and 40% of responding members of the
European Association of Nuclear Medicine, respectively
[29]. In addition, tracers other than FDG were applied by
5%–10% of radiological and by 6%–29% of nuclear
medicine responders, suggesting that similar tendencies
will emerge in new departments like ours. Our survey
suggests that if available, PET/CT is going to be used.
In conclusion, without capacity limitations, the use of
PET/CT increased steeply and linearly during the first
3 years and changed diagnosis and/or staging and/or
treatment plan in about one third of cases. These tendencies
were in line with Danish and European trends, recent
oncological database results from the US, forecasts by
European specialist societies and marketing analyses—all
of which foresee the increasing clinical use of functional at
the expense of anatomical imaging.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Centers for Medicare and Medicaid Services (2002–2009) NCD for
Positron Emission Tomography (PET) Scans (220.6) [Medical
Coverage Database on the Internet]. Centers for Medicare and
Medicaid Services, Baltimore. Available via http://www.cms.hhs.
gov/mcd/viewncd.asp?ncd_id=220.6&ncd_version=4&basket=ncd
%3A220%2E6%3A4%3APositron+Emission+Tomography+%
28PET%29+Scans. Accessed 21 July 2010
2. Hillner BE, Liu D, Coleman RE, Shields AF et al (2007) The
National Oncologic PET Registry (NOPR): design and analysis
plan. J Nucl Med 48:1901–1098
3. Podoloff DA, Advani RH, Allred C et al (2007) NCCN task force
report: positron emission tomography (PET)/computed tomogra-
phy (CT) scanning in cancer. J Natl Compr Cancer Netw 5(Suppl
1):S1–S22
4. Boellaard R (2009) Standards for PET image acquisition and
quantitative data analysis. J Nucl Med 50:11S–S20
5. Boellaard R, O’Doherty MJ, Weber WA et al (2010) FDG PET
and PET/CT: EANM procedure guidelines for tumour PET imaging:
version 1.0. Eur J Nucl Med Mol Imaging 37:181–200
6. Allen-Auerbach M, Weber WA (2009) Measuring response with
FDG-PET: methodological aspects. Oncologist 14:369–377
7. Weber WA (2009) Assessing tumor response to therapy. J Nucl
Med 50:1S–10S
8. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From
RECIST to PERCIST: Evolving Considerations for PET response
criteria in solid tumors. J Nucl Med 50:122S–150S
9. Långström B, Bergström M, Antoni G, Engler E (2001) Uppsala
University PET Centre 1989–2001. Uppsala University PET
Centre, Uppsala
10. About Turku PET Centre–History. Turku PET Centre, Turku.
Available via http://pet.utu.fi/history.html. Accessed 21 July 2010
11. Rodell A (2003) On the trail of inner life. PET in Århus 1993–
2003. Århus PET Center, Århus
12. Danish Institute of Radiation Protection (2009) [The use of
radiopharmaceutical in nuclear medicine examinations and treat-
ments in Denmark 2008]. Danish Institute of Radiation Protection,
Danish National Board of Health, Copenhagen. Available via http://
www.sst.dk/publ/Publ2009/SIS/Nuklear_medicin/Nuklearmedi
cinsk_sammentaelling_2008.pdf. Accessed 21 July 2010
13. European Association of Nuclear Medicine (2006) Status of
nuclear medicine in Europe–2006. EANM’06 statistics survey.
EANM, Vienna
14. European Association of Nuclear Medicine (2007) Status of
nuclear medicine in Europe–2007. EANM’07 statistics survey.
EANM, Vienna
1284 Eur Radiol (2011) 21:1277–1285
15. European Association of Nuclear Medicine (2009) Status of
nuclear medicine in Europe–2009. EANM’09 statistics survey.
EANM, Vienna
16. World Health Organisation (2007) International Statistical Classi-
fication of Diseases and Related Health Problems 10th Revision.
Version for 2007. World Heath Organisation and German Institute
of Medical Documentation and Information. Available from.
http://apps.who.int/classifications/apps/icd/icd10online/. Accessed
21 July 2010
17. Tucker R, Coel M, Ko J, Morris P, Druger G, McGuigan P (2001)
Impact of fluorine-18 fluorodeoxyglucose positron emission
tomography on patient management: first year’s experience in a
clinical center. J Clin Oncol 19:2504–2508
18. Gutte H, Højgaard L, Kjær A (2005) Early clinical experience and
impact of 18F-FDG PET. Nucl Med Commun 16:989–994
19. Gopalan D, Griffiths D, Townsend C, Prvulovich E, Bomanji J,
Costa DC, Ell PJ (2002) Fluorodeoxyglucose positron emission
tomography in clinical oncology: the referrer’s perspective. Nucl
Med Commun 23:1041–1046
20. Hillner BE, Tunuguntla R, Fratkin M (2004) Clinical decision
associated with positron emission tomography in prospective
cohort of patients with suspected or known cancer at one United
States center. J Clin Oncol 22:4147–4156
21. Lau WF, Binns DS, Ware RE, Ramdave S, Cachin F, Pitman AG,
Hicks RJ (2005) Clinical experience with the first combined
positron emission tomography/computed tomography scanner in
Australia. Med J Aust 182:172–176
22. Hillner BE, Siegel BA, Liu D et al (2008) Impact of positron
emission tomography/computed tomography and positron emis-
sion tomography (PET) alone on expected management of
patients with cancer: initial results from the National Oncologic
PET registry. J Clin Oncol 26:2155–2161
23. Hillner BE, Siegel BA, Shields AF et al (2009) The impact of
positron emission tomography (PET) on expected management
during cancer treatment: findings of the National Oncologic PET
Registry. Cancer 115:410–418, Erratum in: Cancer 115:1133
24. Facey K, Bradbury I, Laking G, Payne E (2007) Overview of the
clinical effectiveness of positron emission tomography imaging in
selected cancers. Health Technol 11:iii–iv, xi–267
25. Långström B, Grahnen A, Honoré PH et al (2009) The risk of
exaggerated risk aversion—a life and death struggle for molecular
imaging. Eur J Nucl Med Mol Imaging 36:1693–1694
26. Danish National Board of Health (2006) PET (Positron emission
tomography). Recommendations for the elaboration of PET and
FDG production]. Danish National Board of Health, Copenhagen.
Available via http://www.sst.dk/publ/Publ2006/PLAN/PET/
PET_FDG.pdf. Accessed 21 July 2010
27. Market Research.com (2009) Europe nuclear imaging equipment:
market analysis and opportunity assessment. Available via http://
www.researchandmarkets.com/reports/1195848. Accessed 21 July
2010
28. European Association of Nuclear Medicine (2008) Official
EANM Position: The medical use of radiopharmaceuticals up
to 2025. An exploration of the future medical use of radio-
isotopes. A report written and translated by Technopolis Group,
commissioned by the Dutch Ministry of Housing, Spatial
Planning and the Environment (VROM), and supported by
the Dutch Society of Nuclear Medicine (NVNG) under the lead
of Dr. J.F. Verzijlbergen. Available via https://www.eanm.org/news/
official_eanm_position.php?navId=658. Accessed 21 July 2010
29. Cuocolo A, Bretnach É (2010) Multimodality imaging in Europe:
a survey by the European Association of Nuclear Medicine
(EANM) and the European Society of Radiology (ESR). Eur J
Nucl Med Mol Imaging 37:163–167
Eur Radiol (2011) 21:1277–1285 1285
